Kyongbo Pharmaceutical Co Ltd
Kyongbo Pharmaceutical Co., Ltd manufactures and sells active pharmaceutical ingredients and finished drugs in South Korea and internationally. The company offers general, cephalosporins, and anti-cancer APIs; prescription drugs, including anesthetic, cardiovascular, digestive, and antibiotics; and OTC drugs. It also provides medical devices, including portable X-ray machine and ultrasonic diagno… Read more
Kyongbo Pharmaceutical Co Ltd (214390) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.031x
Based on the latest financial reports, Kyongbo Pharmaceutical Co Ltd (214390) has a cash flow conversion efficiency ratio of 0.031x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩4.51 Billion) by net assets (₩145.28 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Kyongbo Pharmaceutical Co Ltd - Cash Flow Conversion Efficiency Trend (2014–2024)
This chart illustrates how Kyongbo Pharmaceutical Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Kyongbo Pharmaceutical Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Kyongbo Pharmaceutical Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Top High Image
TWO:3284
|
-0.047x |
|
YAS Co., Ltd.
KQ:255440
|
-0.027x |
|
Archer Materials Limited
PINK:ARRXF
|
-0.180x |
|
Medicalg
WAR:MDG
|
-0.001x |
|
DigitalX Limited
OTCQB:DGGXF
|
-0.021x |
|
Ribbon Acquisition Corp Unit
NASDAQ:RIBBU
|
-0.001x |
|
Jung Shing Wire Co Ltd
TW:1617
|
-0.011x |
|
PNB Gilts Limited
NSE:PNBGILTS
|
-1.494x |
Annual Cash Flow Conversion Efficiency for Kyongbo Pharmaceutical Co Ltd (2014–2024)
The table below shows the annual cash flow conversion efficiency of Kyongbo Pharmaceutical Co Ltd from 2014 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩146.15 Billion | ₩149.12 Million | 0.001x | -96.96% |
| 2023-12-31 | ₩144.38 Billion | ₩4.84 Billion | 0.034x | -52.39% |
| 2022-12-31 | ₩143.70 Billion | ₩10.13 Billion | 0.070x | -42.86% |
| 2021-12-31 | ₩145.70 Billion | ₩17.97 Billion | 0.123x | -7.45% |
| 2020-12-31 | ₩156.06 Billion | ₩20.80 Billion | 0.133x | -16.02% |
| 2019-12-31 | ₩149.16 Billion | ₩23.67 Billion | 0.159x | +2177.40% |
| 2018-12-31 | ₩149.01 Billion | ₩-1.14 Billion | -0.008x | -104.19% |
| 2017-12-31 | ₩141.51 Billion | ₩25.81 Billion | 0.182x | -6.84% |
| 2016-12-31 | ₩129.40 Billion | ₩25.33 Billion | 0.196x | +466.96% |
| 2015-12-31 | ₩122.82 Billion | ₩4.24 Billion | 0.035x | -85.29% |
| 2014-12-31 | ₩68.33 Billion | ₩16.04 Billion | 0.235x | -- |